These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21067839)

  • 21. [Changes in liver perfusion caused by transjugular intrahepatic stent shunt (TIPSS)].
    Richter GM; Brado M; Simon C; Mädler U; Radeleff B; Roeren T; Sauer P; Kauffmann GW
    Zentralbl Chir; 1997; 122(2):108-16. PubMed ID: 9173754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Transjugular intrahepatic portosystemic shunt in children. Initial clinical experiences and literature review].
    Huppert PE; Astfalk W; Brambs HJ; Schweizer P; Schott U; Pereira P; Duda SH; Dopfer RE; Claussen CD
    Rofo; 1998 Jun; 168(6):595-603. PubMed ID: 9687952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transjugular intrahepatic portosystemic shunt for liver transplantation.
    Zhou GW; Cai WY; Li HW; Zhu Y; Dodson F; Fung JJ
    Hepatobiliary Pancreat Dis Int; 2002 May; 1(2):179-82. PubMed ID: 14607734
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Covered transjugular intrahepatic portosystemic stents maintain lower portal pressure and require fewer reinterventions than uncovered stents.
    Ockenga J; Kroencke TJ; Schuetz T; Plauth M; Kasim E; Petersein J; Schmidt HH; Lochs H
    Scand J Gastroenterol; 2004 Oct; 39(10):994-9. PubMed ID: 15513340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of transjugular intrahepatic portosystemic shunt on glycometabolism in cirrhosis patients.
    Su AP; Cao SS; Le Tian B; Da Zhang Z; Hu WM; Zhang Y; Wang ZL; Babu SR; Hu T
    Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):53-9. PubMed ID: 22099870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS).
    Jalan R; Redhead DN; Thomas HW; Henderson N; O'Rourke K; Dillon JF; Williams BC; Hayes PC
    Eur J Gastroenterol Hepatol; 1996 Nov; 8(11):1111-6. PubMed ID: 8944375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transjugular intrahepatic portosystemic stent-shunt: technical factors and new developments.
    Tripathi D; Redhead D
    Eur J Gastroenterol Hepatol; 2006 Nov; 18(11):1127-33. PubMed ID: 17033430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NOS2 deficiency increases intestinal metabolism both in nonstimulated and endotoxemic mice.
    Vissers YL; Hallemeesch MM; Soeters PB; Lamers WH; Deutz NE
    Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G747-51. PubMed ID: 14656712
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
    Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
    Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phenprocoumon for prevention of shunt occlusion after transjugular intrahepatic portosystemic stent shunt: a randomized trial.
    Sauer P; Theilmann L; Herrmann S; Bruckner T; Roeren T; Richter G; Stremmel W; Stiehl A
    Hepatology; 1996 Dec; 24(6):1433-6. PubMed ID: 8938176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Restoration of liver function and portosystemic pressure gradient after TIPSS and late TIPSS occlusion.
    Maedler U; Hansmann J; Duex M; Noeldge G; Sauer P; Richter GM
    Cardiovasc Intervent Radiol; 2002; 25(2):148-51. PubMed ID: 11901436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transjugular intrahepatic portosystemic shunt induced short- and long-term cerebral blood flow variations in cirrhotic patients: an arterial spin labeling MRI study.
    Zheng G; Zhang LJ; Cao Y; Pan Z; Qi RF; Ni L; Shi D; Fan X; Lu GM
    Metab Brain Dis; 2013 Sep; 28(3):463-71. PubMed ID: 23564221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt.
    Wannhoff A; Hippchen T; Weiss CS; Friedrich K; Rupp C; Neumann-Haefelin C; Dollinger M; Antoni C; Stampfl U; Schemmer P; Stremmel W; Weiss KH; Radeleff B; Katus HA; Gotthardt DN
    Aliment Pharmacol Ther; 2016 May; 43(9):955-65. PubMed ID: 26919285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acute changes in cerebral blood flow and metabolism during portasystemic shunting.
    Jalan R; Newby DE; Olde Damink SW; Redhead DN; Hayes PC; Lee A
    Liver Transpl; 2001 Mar; 7(3):274-8. PubMed ID: 11244172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preliminary report on portal hypertension treated by transjugular intrahepatic portosystemic stent shunt].
    Wu XJ; Zou ZS; Cao JM
    Zhonghua Wai Ke Za Zhi; 1994 Aug; 32(8):470-3. PubMed ID: 7882770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
    Niederberger M; Ginés P; Martin PY; Tsai P; Morris K; McMurtry I; Schrier RW
    Hepatology; 1996 Oct; 24(4):947-51. PubMed ID: 8855203
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension.
    Afzelius P; Bazeghi N; Bie P; Bendtsen F; Vestbo J; Møller S
    Liver Int; 2011 Oct; 31(9):1381-7. PubMed ID: 21745317
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiac dysfunction in cirrhosis.
    Lee RF; Glenn TK; Lee SS
    Best Pract Res Clin Gastroenterol; 2007; 21(1):125-40. PubMed ID: 17223501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced citrulline availability by OTC deficiency in mice is related to reduced nitric oxide production.
    Luiking YC; Hallemeesch MM; van de Poll MC; Dejong CH; de Jonge WJ; Lamers WH; Deutz NE
    Am J Physiol Endocrinol Metab; 2008 Dec; 295(6):E1315-22. PubMed ID: 18697914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.